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Aﬂatoxin M1 (AFM1) is a hydroxylated metabolite of aﬂatoxin B1 (AFB1). After it is formed,
it is secreted in the milk of mammals. Despite the potential risk of human exposure to
AFM1, data reported in literature on the metabolism, toxicity, and bioavailability of this
molecule are limited and out of date. The aim of the present research was to study the
absorption proﬁle of AFM1 and possible damage to tight junctions (TJ) of the intestinal
Caco-2/TC7 clone grown on microporous ﬁlter supports.These inserts allowed for the sep-
aration of the apical and basolateral compartments which correspond to the in vivo lumen
and the interstitial space/vascular systems of intestinal mucosa respectively. In this study,
the Caco-2/TC7 cellswere treatedwith differentAFM1 concentrations (10–10,000 ng/kg) for
short (40min) and long periods of time (48 h). The AFM1 inﬂux/efﬂux transport and effects
on TJ were evaluated by measuring trans-epithelial electrical resistance and observing TJ
protein (Zonula occludens-1 and occludin) localization. The results showed that: (i) when
introduced to the apical and basolateral compartments, AFM1 was poorly absorbed by the
Caco-2/TC7 cells but its transport across the cell monolayer occurred very quickly (Papp
value of 105.10± 7.98 cm/s× 10−6). (ii) The integrity of TJ was not permanently compro-
mised after exposure to the mycotoxin. Viability impairment or barrier damage did not
occur either. The present results contribute to the evaluation of human risk exposure to
AFM1, although the AFM1 transport mechanism need to be clariﬁed.
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INTRODUCTION
Aﬂatoxins, a group of mycotoxins produced primarily by
Aspergillus ﬂavus and parasiticus, are common contaminants
found in a wide variety of agricultural commodities such as corn,
sorghum,barley, rye,wheat, peanuts, soy, rice, cottonseed, and feed
(Hussein and Brasel, 2001).
Aﬂatoxin B1 (AFB1), the most potent hepatocarcinogen known
in mammals (Creppy, 2002), is biotransformed into aﬂatoxin M1
(AFM1) at the hepatic level by microsomal cytochrome P450
(Van Egmond, 1989) and can be secreted in the milk of mam-
mals (Holzapfel et al., 1966; Applebaum et al., 1982; Van Egmond,
1989; Wood, 1991; Neal et al., 1998). AFM1 has 2–10% of the car-
cinogenic potency of the parent molecule (Creppy, 2002) and is
classiﬁed as a probable human carcinogen, categorized in group
2B by the [International Agency for Research on Cancer , IARC].
Human exposure to AFM1 is partly from consumption of
contaminated milk and dairy products and partly from endoge-
nous production through AFB1 metabolism in the liver (Neal
et al., 1998). Milk has the greatest demonstrated potential for
introducing directly AFM1 in human diet (Rahimi et al., 2010).
AFM1 intake from milk is calculated to be 6.8 ng/person/day in
the European diet, 3.5 ng/person/day in the Latin American diet,
12 ng/person/day in the Far Eastern diet, 0.7 ng/person/day in the
Middle Eastern diet and 0.1 ng/person/day in the African diet
(Creppy, 2002). The potential presence of AFM1 in milk and its
by-products represents a worldwide concern as these products are
primarily consumed by infants and children who are more sus-
ceptible to the adverse effects of mycotoxins (Boudra et al., 2007).
In order to protect consumers, many countries have regulated the
level of AFM1 in milk. The Commission of the European Commu-
nity has prescribed a maximum tolerance limit of 50 ng/kg in milk
and 25 ng/kg in milk-based food for infants [Commission of the
European Communities (CEC), 2004, 2006, 2010], with the inten-
tion of decreasing this limit to 10 ng/kg. The US Food and Drug
Administration (FDA) has however established an action level of
500 ng/kg in whole, low fat, and skim milk (FDA, 2005).
Despite the potential risk of human exposure to AFM1, data
reported in literature regarding the metabolism, toxicity, and
absorption of this molecule, particularly in humans, are limited
and out of date. In general,AFM1 andAFB1 cause almost identical
effects of acute toxicity and carcinogenicity in different mam-
malian systems (Sinnhuber et al., 1970; Pong and Nogan, 1971;
Shibahara et al., 1995). However, AFM1 seems to be the weaker
hepatic carcinogen compared to AFB1 (Bailey et al., 1994) and
little evidence is available with regard to AFM1 embryotoxicity
(Vismara et al., 2006).
A dose-dependent absorption of AFM1 in differentiated Caco-
2 cells and signiﬁcant lactate dehydrogenase release, particularly
evident in undifferentiated cells, was reported previously (Caloni
et al., 2006).
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The purpose of this study was to investigate AFM1 transport
and possible damage to tight junctions (TJ) of Caco-2/TC7 cells, a
clone derived from late passage of the human parental colorectal
adenocarcinoma Caco-2 cell line. This clone was seen to express
higher metabolic competence, such as hydrolase sucrose isoma-
ltase and UDP-glucuronyltransferases (Turco et al., 2011), and
more regular morphology than parental cells and showed more
of a similarity to the in vivo intestinal cells considering certain
deﬁned parameters (Zucco et al., 2005). The experiments were
carried out on microporous ﬁlter supports which separated the
apical (Ap) compartment (corresponding to the in vivo intesti-
nal lumen) from the basolateral (Bl) compartment (which in vivo
faces the interstitial space and the vascular systems) and allowed
for separate evaluation of the absorptive inﬂux (Ap to Bl) and
exsorptive components (Bl to Ap).
MATERIALS AND METHODS
CHEMICALS
The 0.5-ng/μl AFM1 solution in methanol was obtained from
Sigma Chemical Co. (St. Louis, MO, USA). Water (H2O),
acetonitrile (ACN), and methanol (MeOH) for HPLC analy-
sis were obtained from J.T. Baker® (Deventer, The Nether-
lands) and 2-propanol (IPA) from Merck (Darmstadt, Ger-
many). Dimethylsulfoxide (DMSO) was purchased from Carlo
Erba (Milan, Italy). Hanks Balanced Salt Solution (HBSS), N -
2-hydroxyethylpiperazine-N ′-2-ethane sulfonic acid (HEPES),
and 2-(N -morpholino) ethane sulfonic acid (MES) were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA). Dulbecco’s
Modiﬁed Eagles’ Medium (DMEM) high glucose, Fetal Calf
Serum (FCS), glutamine, Non-Essential Amino Acids (NEAA),
penicillin/streptomycin were all purchased from GIBCO BRL
(Gaithersburg, MD, USA). All other chemicals were of analytical
grade.
CELL CULTURE CONDITIONS
Caco-2/TC7 clone, derived from late passage of Caco-2 wild type
cells (provided by Dr. Ming Hu,Washington State University, Pull-
man) was routinely grown in an atmosphere of 5% carbon dioxide
at 37˚C in DMEM high glucose standard medium (Caloni et al.,
2006). The cells were seeded at a density of 1.5× 105 cells/ﬁlter
on 1μm pore size 12-well plate polycarbonate inserts (Millicell®,
Millipore Corporation). The cells were used between passage 60
and 65 and maintained in a standard culture medium (regularly
changed three times a week) during the whole differentiation
phase. The experiments were performed after 21 days of culture
when the differentiation process was completed.
ABSORPTION EVALUATION
Experiment 1
Experiment 1 was performed to evaluate AFM1 in vitro intestinal
absorption proﬁle after exposure for 48 h. Caco-2/TC7 cells were
treated for 48 h with different concentrations of AFM1 (1,000,
5,000, 10,000 ng/kg corresponding to 3.2, 16, 32 nM) in both
Ap and Bl sides. AFM1 was dissolved in DMSO; the same ﬁnal
concentration of the solvent (2% maximum) was used in the cor-
responding control cells. At the end of the incubation time, Ap
and Bl media, and the cellular layer were collected separately and
processed for HPLC analysis.
Experiment 2
Experiment 2 was performed to evaluate AFM1 in vitro intesti-
nal absorption kinetic proﬁle at different times of exposure up to
40min. Caco-2/TC7 cells were treated for 40min with different
concentrations of AFM1 (10, 100, 1,000 ng/kg corresponding to
0.032, 0.32, 3.2 nM) in Phosphate buffer (HBSS) in pH gradient
(HBSS-Mes, pH= 6–6.5, in Ap compartment (donor) and HBSS-
Hepes, pH= 7.2–7.4, in Bl compartment). At different time points
(10, 20, 30, and 40min after exposure), samples of buffer were
taken from the receiver compartment and replaced by an equal
volume of fresh buffer. At the end of the experiments, buffers from
the donor compartments as well as cellular lysates were collected
to allow mass balance calculation. All samples were processed for
HPLC analysis.
BARRIER INTEGRITY ASSAY (TRANS-EPITHELIAL ELECTRICAL
RESISTANCE EVALUATION)
In Experiment 1 and Experiment 2 barrier impairment after expo-
sure to AFM1 was assessed by measuring the trans-epithelial elec-
trical resistance (TEER)which quantiﬁes ionmovement across the
cellular barrier. TEER values were recorded in the culture medium
at 37˚C with chopstick electrodes (Millicell®-ERS, Millipore) and
were expressed as Ω× cm2 according to the following equation:
TEER = (Ω cell monolayer − Ω ﬁlter cell - free) × ﬁlter area.
For each ﬁlter, three separate measures were collected.
FLUORESCENT STAINING OF CELLULAR STRUCTURES
Experiment 3
Experiment 3 was carried out to evaluate the AFM1 effects on
TJ proteins. The expression of Zonula occludens-1 (ZO-1) and
occludin, two TJ proteins located in different cellular compart-
ments, was examined. In addition, considering that apoptosis
might contribute to loss of intestinal barrier integrity (Sun et al.,
1998; Abreu et al., 2000; Gitter et al., 2000; Chin et al., 2002),
nuclear staining was performed as a marker of apoptosis.
In detail, Caco-2/TC7 cells were seeded on ﬁlters as described
previously and treated with AFM1 concentrations of 1,000 ng/kg
(3.2 nM) and 10,000 ng/kg (32 nM) for 60min. After two
washes with PBS, monolayers were ﬁxed with a solution of
paraformaldehyde (4%) and sucrose (0.12M) and permeabilized
with TRITON×-100 (0.2%). For ZO-1 and occludin staining, cells
were incubatedovernight at 4˚Cwith anti-ZO-1 (1:100 inPBS) and
anti-Occludin (1:50 in PBS) and then labeled with the secondary
ﬂuorescent conjugated antibodies. For nuclear staining, after two
washeswith deionizedwater, 250μl of Hoechst solutionwas added
to the Ap compartment and incubated at 37˚C for 30min. Cells
were observed using an inverted ﬂuorescent microscope (LEICA
DM IRB, Nussloch, Germany).
EXTRACTION PROCEDURE FOR HPLC ANALYSIS
After exposure to AFM1 the cells were processed and the samples
were analyzed for AFM1 presence by using HPLC. All procedures
were conducted in absence of artiﬁcial light. In short, 3ml of H2O
was added to eachmediumsample (1ml) and then extracted by the
Immunoafﬁnity Column (Aﬂa M1 TM,Vicam, USA) as described
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by Sharman et al. (1989). The Immunoafﬁnity Column was ﬁrst
conditionedwith 10ml of PBS, subsequently treatedwith the sam-
ple, then washed with 10ml H2O and ﬁnally dried. The AFM1 was
slowly eluted from the column with methanol (2ml) into a glass
vial, dried under nitrogen, and dissolved in 200μl of ACN:H2O
(25:75). Pellet analysis was carried out after adding 100μl of ACN
with subsequent sonication for 15min followed by centrifugation
for 10min 500× g. Supernatantswere analyzedwithout extraction
(Caloni et al., 2006).
HPLC ANALYSIS
Samples were processed as described previously and analyzed by
HPLC (Series 200, Perkin-Elmer, USA) using a Waters Spherisorb
5μm ODS 2 250mm× 4.6mm (Supelco, Inc., Sigma-Aldrich, St.
Louis,MO,USA),MeOH-NaH2PO4 0.1M (33:67, v:v) as a mobile
phase (ﬂow rate of 1ml/min) and a ﬂuorescence detector (LC 240
Perkin-Elmer, USA) set at an excitation wavelength of 365 nm
and emission wavelength of 420 nm (Sharman et al., 1989). AFM1
chromatographic conditions were described by Pietri et al. (1997).
MEDIAN APPARENT PERMEABILITY COEFFICIENT (Papp) VALUE AND
UPTAKE RATIO CALCULATION
The apparent permeability coefﬁcient (Papp) value for both direc-
tions (from Ap to Bl and from Bl to Ap) was calculated using the
following general equation (Prieto et al., 2010; Turco et al., 2011):
CR (t ) = [M/ (VD + VR)]
+ (Cr,0 − [M / (VD + VR)]
)
e−Papp A(1/VD+1/VR)t
where V R is the volume in the receiver compartment and VD is
the volume of the donor compartment. M is the amount of toxin
in the system,A is the area of the ﬁlter,CR,0 is the toxin concentra-
tion in the receiver compartment at the beginning of the interval
and t is the time from the start of the interval.
Uptake ratio (absorption), i.e., the ratio between Ap→Bl and
Bl→Ap Papp values and efﬂux ratio (secretion), i.e., the ratio
between Bl→Ap and Ap→Bl Papp values, were also calculated.
STATISTICAL ANALYSIS
Two separate experiments, performed in triplicate, were carried
out for each assay. Results were expressed as mean± standard
deviations (SD). Statistical evaluation was performed by two
tailed Student’s t -test. The level of signiﬁcance was established
at P< 0.05.
RESULTS
EFFECTS ON TJ
Trans-epithelial electrical resistance
Trans-epithelial electrical resistance values in Experiment 1 were
recorded before the treatment and after exposure for 6 and 24 h
to different concentrations of AFM1 (from 1,000 to 10,000 ng/kg).
Both the Ap and Bl sides were subjected to treatment. The mean
TEER value of untreated cells was 256± 6Ω× cm2.
As shown in Figure 1, a slight (15–20%) but signiﬁcant
(P < 0.01) TEER decrease was reported starting from the sixth
hour of treatment. The reduction was not dose-dependent. This
FIGURE 1 | Effects of AFM1 treatment on Caco-2/TC7 trans-epithelial
electrical resistance (TEER) values. Cells were exposed to different
concentrations of AFM1 (1,000, 5,000, and 10,000 ng/kg) in both Ap and Bl
sides. A slight (15–20%) but signiﬁcant (P<0.01) TEER decrease was
observed starting from the sixth hour of treatment. TEER values were
basically unchanged after treatment for 24 h. Data are the mean of two
separate experiments performed in triplicate±SD.
decrease could indicate an alteration in paracellular permeability
in presence of AFM1.
Trans-epithelial electrical resistance values were basically
unchanged after 48 h of AFM1 treatment (data not shown). Before
and after the 40-min absorption studies (Experiment 2), TEER
values of all inserts were determined in order to verify monolayer
integrity. No signiﬁcant variations were reported at any of the
concentrations tested; moreover, the mean TEER value was always
within the range of the acceptance criteria deﬁned for this cell line
(i.e., >200Ω cm2).
Fluorescent staining of cellular structures
After a 1-h treatment with AFM1 concentrations of 1,000 and
10,000 ng/kg, no loss of ZO-1 was observed. Occludin staining
continuity was reported, indicating integrity of TJ (Figures 2A–I).
Caco-2/TC7 monolayers exhibited uniform ﬂuorescent nuclear
staining (Figures 2J–L) characteristic of viable cells indicating no
apoptotic changes induced by AFM1 at concentrations of 1,000
and 10,000 ng/kg.
RESULTS OF HPLC DETERMINATION
The detection limit for AFM1 in medium and cells in both exper-
iments was 5 ng/kg and the volume injected was 50μl. AFM1
extraction recoveries fromAp andBlmedia samples for each trans-
port study were calculated on 20 replicates, obtaining a range of
91.2–98.5%. Recoveries from Caco-2/TC7 cells extractions were
about 100%.
AFM1 ABSORPTION PROFILE
Absorption of AFM1 was evaluated on the insert culture sys-
tem. Caco-2/TC7 cells were exposed to different concentrations
of AFM1 (1,000–10,000 ng/kg) in both Ap and Bl compartments
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FIGURE 2 | Effects of AFM1 treatment on Caco-2/TC7TJ complex
components ZO-1 and occludin and nuclear structure. No differences
between control and treated monolayer was observed (arrows). (A–C) ZO-1
labeling, (A) control monolayer, (B) monolayer treated with 1,000 ng/kg AFM1
for 1 h, (C) monolayer treated with 10,000 ng/kg AFM1 for 1 h, (D–F) Occludin
labeling, (D) control monolayer, (E) monolayer treated with 1,000 ng/kg AFM1
for 1 h, (F) monolayer treated with 10,000 ng/kg AFM1 for 1 h, (G–I) Merging
of ZO-1, and occludin labeling, (G) control monolayer, (H) monolayer treated
with 1,000 ng/kg AFM1 for 1 h, (I) monolayer treated with 10,000 ng/kg AFM1
for 1 h, (J–L) Nuclear labeling, (J) control monolayer, (K) monolayer treated
with 1,000 ng/kg AFM1 for 1 h, (L) monolayer treated with 10,000 ng/kg AFM1
for 1 h.
anddistributionbetween compartmentswas determined after 48 h
by HPLC analysis. After Ap exposure more than 70% of the myco-
toxinwas found in thedonor compartmentwhile, after Bl exposure
a uniform distribution between donor and acceptor compart-
ments was reported. In both cases, the same low concentration
of mycotoxin was detected in the cells, indicating that no signif-
icant absorption occurred into this cell line (Table 1). Moreover,
the trend was independent of the dose in all the experimental
conditions utilized.
Forty-minutes transport studies were performed with AFM1
concentrations ranging from 10 to 1,000 ng/kg in both Ap and
Bl compartments and distribution in the compartments was
evaluated after 10, 20, 30, and 40min of exposure (Table 2).
A Papp value of 105.10± 7.98 cm/s× 10−6 was obtained for
both passage directions (from Ap to Bl and from Bl to Ap). AFM1
uptake (absorption) and efﬂux (secretion) ratios were <2.
DISCUSSION
The intestinal tract represents theﬁrst barrier to ingested chemicals
or food contaminants and the evaluation of its integrity is crucial
in assessing risk subsequent to food contaminant exposure.
The disruption of the intestinal barrier allows increased pen-
etration of normally excluded luminal substances that could
promote intestinal disorders (Pinton et al., 2009).
Although epidemiological evidence is still required, it is
believed that food-associated exposure to certain mycotoxins
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Table 1 | AFM1 detection in donor compartment, acceptor compartment, and cellular fractions after exposure for 48h.
AFM1 ng/kg Apical exposure (mean±SD) Basolateral exposure (mean±SD)
Donor medium Acceptor medium Cells Donor medium Acceptor medium Cells
1,000 731.7±91.8 163.6±9.1 53.1±9.3 339.2±77.8 451.6±48.0 59.3±7.5
5,000 4324.4±297 149.0±34.4 59.2±8.3 2178.7±239.2 2330.9±111.8 60.2±9.0
10,000 7341.7±450 1914.5±391.5 53.1±9.2 3984.2±497.8 4611.8±449.1 60.5±7.6
Results are the mean of two separate experiments performed in triplicate±SD.
Table 2 | AFM1 detection in donor compartment, acceptor compartment, and cellular fractions after exposure for 40min.
AFM1 ng/kg Time (min) Apical exposure (mean±SD) Basolateral exposure (mean±SD)
Donor medium Acceptor medium Cells Donor medium Acceptor medium Cells
10 10 NA 0.63±0.21 NA NA 0.57±0.06 NA
20 NA 1.35±0.21 NA NA 0.93±0.25 NA
30 NA 2.47±0.15 NA NA 1.30±0.20 NA
40 7.23±0.31 3.77±0.35 NA 5.97±0.59 2.17±0.31 NA
100 10 NA 4.53±0.67 NA NA 4.50±0.26 NA
20 NA 5.53±0.15 NA NA 10.60±1.57 NA
30 NA 6.80±0.60 NA NA 17.17±1.07 NA
40 71.83±2.28 9.33±0.15 14.83±3.12 65.73±2.64 21.37±1.96 7.30±1.41
1,000 10 NA 51.97±2.52 NA NA 34.17±1.33 NA
20 NA 66.30±4.52 NA NA 88.27±3.56 NA
30 NA 89.47±4.52 NA NA 121.67±6.50 NA
40 718.93±5.75 104.20±1.95 48.87±3.31 606.47±24.45 228.73±5.42 33.35±1.20
NA, not analyzed.
Results are the mean of two separate experiments performed in triplicate±SD.
could lead to the induction and/or persistence of human chronic
intestinal inﬂammatory diseases (Maresca and Fantini, 2010).
Moreover, existing data demonstrate that several mycotoxins, at
realistic doses, are able to affect key intestinal and immune func-
tions such as composition of the intestinal microﬂora (Tenk et al.,
1982; Waché et al., 2009), production of mucus (Obremski et al.,
2008), epithelial barrier function (Gratz et al., 2007; Lambert et al.,
2007; McLaughlin et al., 2009; Pinton et al., 2009; Van De Walle
et al., 2010), bacterial translocation (Maresca et al., 2008), and
innate and adaptive gut immunity (Fukata et al., 1996; Oswald
et al., 2003; Li et al., 2005, 2006; Bouhet et al., 2006).
AFM1, present in milk and dairy products, is of great impor-
tance because of the high consumption of these products by
humans, especially children. Human exposure to AFM1 through
milk and dairy products has been shown in several studies
(Sassahara et al., 2005; Unusan, 2006).
The intake of AFM1 from milk is calculated to be
6.8 ng/person/day in the European diet but it is interesting to note
that if all milk consumed were contaminated with AFM1 at the
proposed maximum EU levels of 50 ng/kg, the intake of AFM1
from milk in the European regional diet would be 15 ng/person
per day [Joint FAO/WHO Expert Committee on Food Addi-
tives (JECFA), 2001]. Considering a tolerable daily intake (TDI)
of 0.2 ng/kg b.w. (14 ng/person with a mean weight of 70 kg) as
calculated by Kuiper-Goodman (1990), an intake of 15 ng/person
per day as estimated in the European regional diet could repre-
sent a signiﬁcant dose (Prandini et al., 2009). In the assessment
of human exposure to mycotoxins in dairy milk carried out by
Coffey et al. (2009) AMF1 resulted as the toxin of greatest concern
as, in certain circumstances, its concentration exceeded the EU
limit in milk (Commission of the European Communities (CEC),
2004, 2006, 2010). Infants, considering their milk-based diet, rep-
resent the population most exposed to this toxin (Turconi et al.,
2004).
The toxicological effects of AFM1 are much less investigated
than the ones caused by AFB1 and limited data are reported in
literature regarding its absorption and metabolism, particularly in
humans.
A previous study (Caloni et al., 2006) demonstrated a higher
toxicity of AFM1 in Caco-2 undifferentiated cells than in differen-
tiated ones, in which GSH transferase enzyme is highly expressed.
This suggests, as reported by Neal et al. (1998), a phase II con-
jugation mechanism. Roda et al. (2010) seem to conﬁrm this
detoxiﬁcation pathway, as AFM1 was seen to affect the imma-
ture human erythroid progenitor cells more markedly than the
respective more mature cells.
AFM1 absorption was previously evaluated in Caco-2 cells
cultured in monolayer (Caloni et al., 2006) demonstrating a
dose-dependent passage of the mycotoxin, particularly evident in
21-day differentiated cells.
www.frontiersin.org June 2012 | Volume 3 | Article 111 | 5
Caloni et al. Aﬂatoxin M1 in vitro exposure
In the present paper, we investigated the absorption proﬁle of
AFM1 and possible damage to TJ of Caco-2/TC7 cells cultured on
microporous ﬁlter supports for 21 days. The Caco-2/TC7 cell line
is as suitable as the parental Caco-2 line as an intestinal model
for studying absorption. Furthermore, due to its clonal origin, the
TC7 cell line shows a less heterogenic cellular population, which
can result in better reproducibility of results (Chantret et al., 1994;
Turco et al., 2011).
In epithelial tissue the initial toxic effect of several substances
seems to be directed at the molecules involved in the junctional
complexes (tight and adherens junctions); for this reason changes
in the permeability of epithelial barriers can be considered as early
indicators of adverse effects after chemical exposure (Sambuy,
2009).
In this study, the effects of AFM1 on TEER were initially stud-
ied. The TEER quantiﬁes ion movement across a monolayer and is
considered to be a good indicator of the integrity of epithelial bar-
rier. A slight (15–20%) but signiﬁcant (P < 0.01) TEER decrease,
unrelated to the dose, was reported starting from the sixth hour of
treatment. This decrease could indicate an alteration in paracel-
lular permeability in the presence of AFM1. A reduction in TEER
can however be caused by different events including: (i) increase
in paracellular permeability to ions; (ii) changes in transcellular
ion ﬂux through altered plasma membrane channels or pumps;
or (iii) uncontrolled cell death within the monolayer (Madara,
1998). In the present work, the third option must be excluded
since the cellular monolayer was completely intact at the end of
the experiments.
Modulation of barrier properties is often mirrored by changes
in speciﬁc TJ protein components, since TJ dynamic structures
respond quickly to several physiological and pathological stim-
uli. We therefore examined whether the AFM1-induced reduction
of TEER could be due to changes in the expression of certain TJ
proteins. We focused our attention on the expression of two TJ
proteins located in different cellular compartments: ZO-1 inter-
acting in the cytoplasm with actin cytoskeleton and occludin
interacting throughout its extracellular domain with neighbor-
ing cells (McLaughlin et al., 2004; Schneeberger and Lynch, 2004).
As expected, the localization of TJ proteins showed strong periph-
eral labeling in control Caco-2/TC7 cell monolayers. The overall
morphology of cells treated with AFM1 remained unchanged.
Treatment with AFM1 did not affect ZO-1 or occludin staining
or localization. Nuclear staining was also performed in Caco-2-
TC7 cells and in this case monolayers exhibited characteristically
uniform ﬂuorescent nuclear staining throughout all nuclei indi-
cating no apoptotic changes induced by AFM1 at any of the
concentrations tested.
The AFM1 absorption proﬁle was evaluated on the insert cul-
ture system. In this condition the cells, after about 3weeks of
culture, were able to polarize and fully differentiate according to
the enterocytic pathway, with apical microvilli and a differentiated
basolateral surface, similar to the cellular surface in contact with
sub-epithelial tissue. In both treatments, a very low concentration
of mycotoxin was detected in the cells, indicating that AFM1 was
poorly absorbed by these cells. Under these experimental condi-
tions, AFM1 passage through the Caco-2/TC7 layer was observed
at all tested concentrations after both Ap and Bl exposure and the
Papp value conﬁrmed AFM1 to be a molecule highly absorbed by
the intestine (Prieto et al., 2010; Turco et al., 2011).
In particular, its passage was greater in the Bl-Ap direction than
in the Ap-Bl one. The presence of asymmetric passage through
Caco-2 monolayer usually suggests involvement of transporter
pathways. This cell line expressed most of the known intestinal
transporters overseeing inﬂux/efﬂux carrier mediated processes,
in a pattern similar to that reported for the small intestine (Sun
et al., 2008). The AFM1 absorption proﬁles in both experiments
were similar to the ones reported with zearalenone (Videmann
et al., 2008) and fumonisin B1 metabolites (De Angelis et al.,
2005), where the involvement of an active mechanism of trans-
port was hypothesized. Otherwise the calculated AFM1 uptake
and efﬂux ratios (<2), suggested the inclusion of this mycotoxin
in the group of compounds passively transported by paracellular
or intracellular route, since xenobiotics generally considered active
or carrier-mediate transported show an efﬂux or an uptake ratio
>2 (Zhang et al., 2007).
In conclusion,our results pointed out thatAFM1: (i) was poorly
absorbed inCaco-2/TC7 cells under the present experimental con-
ditions, (ii) passed across the monolayer in both directions (from
Ap to Bl and from Bl to Ap), even if to a different extent, (iii) did
not cause viability impairment or barrier damage. Further stud-
ies need to be conducted in order to better understand the AFM1
transport mechanism.
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